Integrated Oncology Discovery Solutions
End-to-end platform from target validation through IND enablement. 100+ validated tumor models, advanced In vivo imaging, DMTA integration, and proven clinical translation.
Executive Summary
Aragen’s Integrated Oncology Discovery Solutions translate bold cancer research concepts into regulatory-ready drug candidates. We function as a seamless extension of your team, unifying chemistry, biology, pharmacology, and DMPK under a single precision-guided platform. From target engagement assays through human xenografts, syngeneic models, patient-derived xenografts, and real-time bioluminescence imaging, we deliver the science, speed, and rigor oncology programs demand.
Why Choose Aragen for Oncology
Massive Pre-Validated Infrastructure
(80+ human xenografts, 10+ syngeneic models, 4 PDX model)
Zero Logistics Lag
Chemistry, biology, pharmacology, and DMPK all under one roof. Closed-loop DMTA cycles eliminate inter-vendor shipping delays, enabling real-time collaboration and faster decision-making than distributed competitors.
Advanced Imaging Technology
- Bioluminescence imaging (BLI) for real-time CNS penetration assessment
- Fluorescence imaging (FLI) for biodistribution tracking
- Orthotopic, subcutaneous, and dispersed tumor models
- Automated tumor measurement and progression monitoring
- Integration with PK/PD for mechanistic correlations
Comprehensive Tumor Model Portfolio
Validated Human Xenograft Models Across Multiple Cancer Types
Aragen offers a broad portfolio of validated human xenograft models that support efficacy assessment, biomarker discovery, PK/PD evaluation, and translational oncology research. These models span both solid tumors and hematological malignancies and can be integrated with imaging, pathology, and bioanalytical services to generate robust decision-enabling data.
Human Xenograft Models
| S. No. | Cell line | Origin of Tumor |
| 1 | KASUMI-1 | Acute Myeloid leukemia |
| 2 | MOLM-13 | Acute Myeloid leukemia |
| 3 | MV4-11 | Beta myelomonocytic leukemia |
| 4 | NALM-6 | B-Cell leukemia |
| 5 | SUDHL-10 | B-Cell leukemia |
| 6 | Daudi | B-cell lymphoma |
| 7 | SU-DHL-5 | B-cell lymphoma |
| 8 | NCI-H1650 | Bronchoalveolar Carcinoma |
| 9 | HT-1376 | Bladder Cancer |
| 10 | MDA-MB-468 | Breast cancer |
| 11 | MDA-MB-231, MDA-MB-231-Fluc | Breast cancer |
| 12 | MCF-7, MCF-7-Fluc | Breast cancer |
| 13 | SK-Br-3 | Breast cancer |
| 14 | Raji, Raji-Fluc-GFP | Burkitt’s lymphoma |
| 15 | FaDu | Cervical carcinoma |
| 16 | K562 | Chronic myelogenous leukemia (CML) |
| 17 | DLD-1 | Colon adenocarcinoma |
| 18 | LoVo | Colon adenocarcinoma |
| 19 | HT-29 | Colon adenocarcinoma |
| 20 | HCT-116, HCT-116-Luc | Colon adenocarcinoma |
| 21 | Colo 205 | Colon adenocarcinoma |
| 22 | SW480 | Colon adenocarcinoma |
| 23 | KM-12 | Colon adenocarcinoma |
| 24 | A431 | Epidermoid carcinoma |
| 25 | A-673, A-673-Fluc | Ewings sarcoma |
| 26 | MKN-1-Fluc | Gastric cancer |
| 27 | U-87 MG, U-87 MG-Fluc | Glioblastoma |
| 28 | Hep 3B | Hepatocellular carcinoma |
| 29 | Hep G2.2.15 | Hepatocellular carcinoma |
| 30 | PLC/PRF/5 | Hepatoma |
| 31 | NCI-H1573 | Lung adenocarcinoma |
| 32 | Calu-6 | Lung anaplastic carcinoma |
| 33 | A549, A549-Fluc-GFP | Lung cancer (NSCLC) |
| 34 | NCI-H226 | Lung cancer (NSCLC) |
| 35 | H1299 | Lung cancer (NSCLC) |
| 36 | NCI-H358 | Lung cancer (NSCLC) |
| 37 | NCI-H1944 | Lung cancer (NSCLC) |
| 38 | NC-H2122 | Lung cancer (NSCLC) |
| 39 | NCI-H1975 | Lung cancer (NSCLC) |
| 40 | NCI-H460 | Large cell lung carcinoma |
| 41 | A427 | Lung carcinoma |
| 42 | A375 | Melanoma |
| 43 | SK-MEL-1 | Melanoma |
| 44 | MeWo-Rluc* | Melanoma |
| 45 | NCI-H292 | Mucoepidermoid pulmonary carcinoma |
| 46 | IM-9 | Multiple myeloma |
| 47 | KG-1 | Multiple myeloma |
| 48 | NCI-H929 | Multiple myeloma |
| 49 | U266 | Multiple myeloma |
| 50 | MM1.S | Multiple myeloma |
| 51 | RPMI8226 | Multiple myeloma |
| 52 | A673-Luc* | Muscle (Ewing’s Sarcoma) |
| 53 | WSU-DLCL-2* | Non-Hodgkin’s Lymphoma |
| 54 | IGROV-1* | Ovarian cancer |
| 55 | SK-OV-3, SK-OV-3-Fluc | Ovarian cancer |
| 56 | OVCAR-3 | Ovarian adenocarcinoma |
| 57 | OV90 | Ovarian cancer |
| 58 | PANC-01 | Pancreatic cancer |
| 59 | AsPC-1 | Pancreatic cancer |
| 60 | BxPC3, BxPC3-Fluc-GFP | Pancreatic cancer |
| 61 | PANC.10.05 | Pancreatic cancer |
| 62 | MIA-PaCa-2, MIA-PaCa- 2-Rluc | Pancreatic cancer |
| 63 | FaDu | Pharynx Squamous Cell Carcinoma |
| 64 | 22rv.1 | Prostate cancer |
| 65 | LNCaP | Prostate cancer |
| 66 | DU-145 | Prostate cancer |
| 67 | PC-3 | Prostate cancer |
| 68 | 786-O, 786-O-Fluc | Renal cell carcinoma |
| 69 | A498 | Renal cell carcinoma |
| 70 | Caki-1, Caki-1-Fluc | Renal cell carcinoma |
Supporting Capabilities
Validated Syngeneic Tumor Models for Immuno-Oncology Research
Aragen’s syngeneic tumor models enable evaluation of immunotherapies in an intact immune system. These models support checkpoint inhibitors, immune-modulating agents, cell therapies, and combination treatment strategies while providing insights into tumor-immune interactions and therapeutic response.
Syngeneic Tumor Models
| No. | Cell line | Origin of Tumor |
| 1 | 4T1 | Breast Cancer |
| 2 | EMT6 | Breast Cancer |
| 3 | MC38 | Colon Cancer |
| 4 | CT26 | Colon Cancer |
| 5 | A20 | Lymphoma |
| 6 | EG7 | Lymphoma |
| 7 | EL4 | Lymphoma |
| 8 | B16F10 | Melanoma |
| 9 | RENCA | Renal Carcinoma |
Supporting Capabilities
Orthotopic and Imaging-Enabled Models for Translational Oncology
Orthotopic models provide a clinically relevant tumor microenvironment by establishing tumors within the organ of origin. Combined with advanced imaging technologies, these models allow longitudinal monitoring of disease progression, therapeutic response, metastasis, and biodistribution.
Advanced Imaging Integration
Together, these human xenograft, syngeneic, and orthotopic model platforms provide comprehensive support for oncology programs ranging from early efficacy screening to IND-enabling development.
Core Capabilities
Orthotopic & Imaging
Anatomically relevant tumor implantation, real-time bioluminescence for CNS models, metastasis tracking in dispersed models, X-ray and longitudinal imaging, stereotaxic brain dosing.
Pharmacokinetics & Bioavailability
Plasma and tumor tissue exposure analysis, PK/PD correlation studies, LC-MS/MS bioanalysis of complex matrices, MSD platform for multiplex biomarker profiling, ELISA and HTRF assay capabilities.
Mechanistic Biomarkers
Cell cycle regulators (CDK2, CDK4, pRb), inflammatory cytokines (IL-1β, IL-6, IL-10, IL-17, TNF-α, IFN-γ), target engagement assays (SPR, NanoBRET, CETSA), histopathology and digital pathology, gene expression profiling.
Chemistry Integration
AI-guided compound design and synthesis, rapid parallel synthesis for SAR, scaffold hopping and lead optimization, ADC bioconjugation, PROTAC and glue degrader expertise, closed-loop DMTA integration.
Immuno-Oncology
Aragen supports immuno-oncology programs through a portfolio of validated syngeneic and immune-competent tumor models that enable the evaluation of checkpoint inhibitors, immune modulators, cell therapies, and combination treatment strategies. These models preserve tumor–immune system interactions and provide translational insights into immune activation, tumor response, and resistance mechanisms.
Validated Syngeneic Models
- 4T1 Breast Cancer – metastatic breast cancer model for immune response characterization and checkpoint inhibitor evaluation
- B16F10 Melanoma – widely used for immunotherapy efficacy and tumor microenvironment studies
- RENCA Renal Carcinoma – supports assessment of immune-mediated anti-tumor activity
- CT26 Colon Carcinoma – enables evaluation of checkpoint blockade and combination therapies
- MC38 Colon Carcinoma – translational model for T-cell activation and immune-oncology research
Integrated Immuno-Oncology Capabilities
- Syngeneic efficacy studies in immunocompetent systems
- Immune cell profiling using multicolor flow cytometry
- Immunohistochemistry-based immune characterization
- Tumor microenvironment analysis
- T-cell infiltration and activation studies
- Cytokine and chemokine profiling
- Immune biomarker assessment using MSD, ELISA, and HTRF platforms
- Combination efficacy studies involving checkpoint inhibitors, biologics, and small molecules
- PK/PD and biomarker correlation studies
- Histopathology and digital pathology support
By integrating validated syngeneic models with advanced immune profiling, pathology, and biomarker assessments, Aragen enables a comprehensive understanding of therapeutic mechanisms, immune engagement, and efficacy outcomes, helping accelerate the development of next-generation immunotherapies from discovery through IND-enabling studies.
End-to-End Workflow
Target Biology Validation
Target engagement assays, recombinant protein production, stable reporter cell lines, deep mechanistic biomarker profiling. De-risk from day one.
Hit Identification
AI-guided chemistry, phenotypic screening in 3D tumor models, high-content imaging, multiplex cytokine profiling for compound selection.
Lead Optimization
Rapid DMTA cycles, DMPK stress-testing, CYP profiling, permeability studies (Caco-2/MDCK), PK/PD correlation.
In Vivo Translation
Gold-standard tumor models with orthotopic/metastatic staging, stereotaxic brain dosing, real-time bioluminescence imaging, immune profiling.
IND Enablement
Integrated toxicology, exposure-response modeling, submission-ready bioanalytics, regulatory-aligned documentation.
Proven Case Studies
Imaging-Integrated Oncology Models:
U87MG-Luc Brain Orthotopic (real-time CNS penetration with bioluminescence), A549-Luc Lung Orthotopic (metastasis tracking and microenvironment modeling), BxPC-3 Pancreatic Orthotopic (challenging tumor accessibility with imaging validation), Dispersed Lymphoma Raji-LUC (systemic disease progression monitoring).
Value: Predictive power through anatomically relevant models with real-time readouts.
Advanced Technology Integration:
Alzet and iPRECIO Continuous Infusion (clinical-relevant PK/PD with steady-state exposure), PK-PD Correlation Studies (integrated dose selection and biomarker strategy), Nephrotoxicity Assessment (safety evaluation with mechanistic endpoints).
Value: Sophisticated endpoints beyond standard efficacy.
Modality Expertise (PROTACs & Novel):
OVCAR-3 PROTACS Efficacy (targeted protein degradation assessment), Infusion-Based Studies (complex dosing regimens for advanced therapeutics), Bioaccumulation Kinetics (NIR-bevacizumab tracking for biodistribution).
Value: First-mover advantage in next-generation modalities.
InCoRe Digital Platform
Proprietary integrated platform for real-time DMTA tracking, project data visibility, and seamless collaboration. Log in anytime to monitor your oncology program’s progress.
Modality Breadth
Small molecules, PROTACs, glues, monoclonal antibodies, bispecific antibodies, ADCs, and nucleic acids (siRNA, ASOs). Coverage spans solid tumors, melanoma, blood cancers, and rare genetic malignancies.
